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Introduction
The hematopoietic system is built upon the ordered self-renewal and differentia-
tion of hematopoietic stem cells (HSC) within the bone marrow (BM). This process
involves intrinsic and extrinsic cues including both cellular and humoral regulatory
signals generated by the HSC microenvironment, termed as “niche”. The cellular
composition of this “niche” is heterogeneous, including endothelial cells,1
osteoblasts,2 adipocytes, and mesenchymal stem/progenitor cells (MSPC), a com-
mon progenitor for many of the cell lineages comprising the HSC niche.3-5 For fate
decisions, regulatory signals from the BM microenvironment are transmitted to
HSC through intercellular interactions within the proximity of the endosteal sur-
face, the perivascular space, soluble factors, and the extracellular matrix.6 These cel-
lular and humoral regulatory signals dictate the fates of HSC, including self-renewal,
proliferation, differentiation, and apoptosis.7 In addition, there is increasing evi-
dence suggesting a role of the hematopoietic microenvironment in hematopoietic
disorders, such as myeloproliferative neoplasms8,9 and myelodysplastic syndrome.10
Fanconi anemia (FA) is a complex inherited disorder caused by germline muta-
tions in at least one of 16 genes including FANCA, -B, -C, -D1, -D2, -E, -F, -G, -I, -
Fanconi anemia is a complex heterogeneous genetic disorder with ahigh incidence of bone marrow failure, clonal evolution to acutemyeloid leukemia and mesenchymal-derived congenital anomalies.
Increasing evidence in Fanconi anemia and other genetic disorders points
towards an interdependence of skeletal and hematopoietic development,
yet the impact of the marrow microenvironment in the pathogenesis of the
bone marrow failure in Fanconi anemia remains unclear. Here we demon-
strated that mice with double knockout of both Fancc and Fancg genes had
decreased bone formation at least partially due to impaired osteoblast dif-
ferentiation from mesenchymal stem/progenitor cells. Mesenchymal
stem/progenitor cells from the double knockout mice showed impaired
hematopoietic supportive activity. Mesenchymal stem/progenitor cells of
patients with Fanconi anemia exhibited similar cellular deficits, including
increased senescence, reduced proliferation, impaired osteoblast differenti-
ation and defective hematopoietic stem/progenitor cell supportive activity.
Collectively, these studies provide unique insights into the physiological
significance of mesenchymal stem/progenitor cells in supporting the mar-
row microenvironment, which is potentially of broad relevance in
hematopoietic stem cell transplantation.
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ABSTRACT
J, -L, -M, -N, -O, –P, and –Q.11-19 Clinically, FA is a chromo-
somal fragility disorder characterized by progressive BM
failure (BMF), variable developmental anomalies, and a
strong propensity to develop cancer. The risk of developing
BMF by 40 years of age is as high as 90%, and the cumu-
lative incidence of hematologic and non-hematologic
malignancies was reported to be as high as 33% and 28%,
respectively.20 In the natural course of the disease, FA
patients develop progressive pancytopenia, indicating that
the defect occurs at the level of HSC.21-23 FA patients have a
high incidence of inherited skeletal malformations and
osteoporosis,20,24 suggesting a role of FA proteins in osteoge-
nesis and bone maintenance. Despite these clinical obser-
vations of multiple mesenchymal defects in FA and our
increasing awareness of the interdependence between the
BM niche and hematopoiesis, relatively little attention has
been directed to investigating the putative association
between abnormal HSC function and the BM niche in FA.
MSPC are a major component of the hematopoietic
niche and have been shown to serve a critical function as
hematopoiesis-supporting stromal cells.25 Here, we report
that defective MSPC are pivotal mediators in the patho-
genesis of hematopoietic defects in Fancc-/-;Fancg-/- double
knockout (DKO) mice. Our studies provide detailed cellu-
lar and molecular evidence implicating mesenchymal cells
as contributory to the BMF in FA, indicating the potential
utility of MSPC/HSC co-transplantation, which may
improve treatment of BMF in FA.
Methods
Animals and reagents
The Fancc and Fancg double heterozygous mice used in this
study have been described previously.26-28 These mice were back-
crossed into a C57BL/6J strain and were then bred to produce
Fancc-/-;Fancg-/- (DKO) and wild-type (WT) mice. Age- and gender-
matched DKO and WT mice were used for all experiments. All
protocols were approved by the Institutional Animal Care and Use
Committee at Indiana University School of Medicine. Chemicals
were obtained from Sigma (St. Louis, MO, USA) unless otherwise
indicated.
Isolation and expansion of mesenchymal 
stem/progenitor cells
MSPC from mice were generated as previously described.29
Briefly, BM mononuclear cells (BMMNC) were separated by low-
density gradient centrifugation from 6- to 8-week-old, age- and
gender-matched WT and DKO mice, then cultured in complete
mouse MesenCult medium (Stem Cell Technologies Inc,
Vancouver, Canada) at 37°C in 5% CO2. MSPC between passage
five to ten were used for the following experiments. The pheno-
typic analyses of MSPC were performed by evaluating the expres-
sion of surface markers including CD44, CD105, CD146, CD29
on a FACS Calibur flow cytometer as previously described.30 For
human MSPC isolation, whole BM cells from FA patients and
healthy donors were cultured in Dulbecco modified Eagle medium
(DMEM)/F12 (Gibco, Carlsbad, USA), containing 10% fetal
bovine serum (Hyclone, South Logan, USA), 1x Insulin transferrin
selenium-A (Life Technologies, Carlsbad, USA), 10 ng/mL human
epidermal growth factor (Peprotech, Rocky Hill, NJ, USA), and 10
ng/mL human platelet-derived growth factor-BB (Peprotech) at
37°C in 5% CO2 and 5% O2 in a fully humidified atmosphere.
MSPC at passage three to five were used for the following exper-
iments.
Micro-computed tomography 
To evaluate trabecular microarchitecture in the distal femoral
metaphysis, fixed femora were scanned using a high-resolution
desktop micro-computed tomography imaging system (μCT-20;
Scanco Medical AG, Basserdorf, Switzerland). The region of inter-
est was defined as 15% of the total femur length measured from
the tip of the femoral condyle and extending proximally for 200
slices with an increment of 9 µm, and was subsequently recon-
structed, filtered (σ= 0.8 and support = 1.0), and thresholded (at
22% of the possible gray scale value) for analysis, as described
elsewhere.31 Trabecular bone was contoured manually within the
trabecular compartment, excluding the cortical shell. The parame-
ter of micro-architecture for bone volume fraction (BV/TV, %) was
measured.
Histomorphometric measurements
Upon sacrifice, the isolated bones were fixed in 10% neutral
buffered formalin for 48 h, dehydrated in graded ethanol, and
embedded undecalcified in methyl methacrylate. Sagittal sections
(5 µm thick) were cut from the middle of the femur. Tartrate-resis-
tant acid phosphatase (TRAP) staining was performed using a
leukocyte acid phosphatase kit (Sigma Diagnostics, St. Louis, MO,
USA) and McNeal staining was performed using the McNeal tetra-
chromat kit (Polysciences, Warrington, PA, USA), both according
to the manufacturers’ protocols. One section per femur was
viewed at 100x magnification on a Leitz DMRXE microscope
(Leica Mikroskopie und System GmbH, Wetzlar, Germany).
Images were captured using a QImaging camera and QCapture-
Pro software (Fryer Company Inc., Cincinnati, OH, USA). The
region of interest for the metaphysis was defined by a rectangular
area, which begins 0.5 mm proximal to the midpoint of the
growth plate, non-inclusive of cortical bone, and extends proxi-
mally for a total area of approximately 2.8 mm2. 
Bone remodeling measurement
Fluorochrome labeling of the bones was performed by
intraperitoneal injections of calcein (20 mg/kg, 8 days before sac-
rifice) and alizarin (20 mg/kg, 4 days before sacrifice), as previ-
ously described.32 Trabecular bone turnover was assessed by
measuring the extent of single-labeled surface (sLS), double-
labeled surface (dLS) and the surface of the bone (BS) between
the calcein and alizarin labels using Image Pro Plus version 4.1
software (Media Cybernetics, Silver Spring, MD, USA). Derived
histomorphometric parameters included: (i) mineralizing surface
(MS/BS), a measure of active bone-forming surface, calculated as
(dLS+sLS/2)/BS; (ii) mineral apposition rate (MAR, μm/ day), a
measure of the rate of radial expansion of new bone, calculated
as Thickness/4 day; and (iii) bone formation rate, an overall
measure of bone formation that combines MS/BS and MAR, cal-
culated as MS/BS × MAR.
Other methods
Methods for the clonogenic assay, bone mineral density quan-
tification, annexin V/propidium iodide staining, senescence assay,
thymidine incorporation assay, purification of HSPC, long-term
culture of HSPC on MSPC monolayers, detection of reactive oxy-
gen species (ROS), osteoblast and adipocyte differentiation of
MSPC, reciprocal transplantation and co-transplantation of FA
BMMNC and MSPC in NS2 mice are described in detail in the
Online Supplementary Methods.
Statistics
Survival curves were compared using the log-rank test.
Differences between two groups with equal variances were
assessed by two-tailed Student t-tests. Multiple comparisons were
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Figure 1. Poor survival and hematopoietic defects in double knockout mice. (A) Survival curves of WT and DKO recipients following transplantation with either WT (n =
11) or DKO (n = 11) BM cells were monitored over a duration of 20 months. (P<0.01, log-rank test). (B) Total number of colony-forming unit-cells (CFU-C) in five sets of
DKO as compared to WT recipient mice transplanted with either WT or DKO BM cells; data are presented as mean ± SEM, **P<0.01, ***P<0.001, two-way ANOVA fol-
lowed by the Bonferroni test. (C) Representative photomicrographs demonstrated BM histology of recipient mice 15 months post-transplantation at low (10×, a-d) and
high (40×, e-h) magnification. Scale bar: 100 μm for a-d, and 10 μm for e-h. (D) Representative H&E-stained sections of spleens from transplanted recipients are shown
at low (10×, a-d) and high (40×, e-h) magnification. Scale bar: 100 μm for a-d, and 10 μm for e-h. (E) Representative May-Grünwald-Giemsa stained peripheral blood
smears of transplanted recipient mice are shown. The peripheral blood smear of DKO recipient mice with WT or DKO BM cells showed dysplastic features including mono-
cytes (f-h, green arrows) and bilobed neutrophils (b-d, red arrows) which were consistent with pseudo Pelger-Huët cells. Scale bar: 10 μm. 
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Figure 2. Double knockout mice had
retarded growth and impaired bone
mineralization. (A) DKO mice had
decreased whole body bone mineral
density (BMD) (n=20 mice per geno-
type) as compared to WT mice. Data are
presented as mean ± SEM, **P<0.01,
two-tailed Student t-test. (B) DKO mice
had decreased BMD as compared to
WT littermates at varying ages. Data are
presented as mean ± SEM, *P<0.05,
**P<0.01, ***P<0.001, two-tailed
Student t-test. (C) Micro-computed
tomography demonstrated that DKO
mice had reduced femoral trabecular
bone volume as compared to WT mice
(n=8 mice per genotype). Data are pre-
sented as mean ± SEM of bone volume
per tissue volume (BV/TV), *P<0.05,
two-tailed Student t-test. (D)
Representative micro-computed tomog-
raphy reconstructions of WT and DKO
mouse femora. Scale bar: 1 mm. (E)
Representative H&E (a-d) and McNeal
staining (e-h) analysis of the femora of
WT and DKO mice. Red arrows indicate
the osteoblasts on the bone surface.
Scale bar: 200 μm for a, c, e, g and 50
μm for b, d, f, h. (F) DKO mice had
reduced numbers of osteoblasts on the
trabecular bone surface (Ob.No./BS) as
compared to WT mice (n=20 mice per
genotype). Data are presented as mean
± SEM, *P<0.05, two-tailed Student t-
test. (G) DKO mice had increased osteo-
clasts along the trabecular bone sur-
face (Oc.S/BS) as compared to WT mice
(n=8 mice per genotype). Data are pre-
sented as mean ± SEM, *P<0.05, two-
tailed Student t-test. (H, I) Bone remod-
eling studies demonstrated that DKO
mice had reduced MS/BS and MAR as
compared to WT mice (n=3 mice per
genotype). Data are presented as mean
± SEM, *P<0.05, two-tailed Student t-
test.
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conducted with one- or two-way analysis of variance (ANOVA)
followed by an appropriate post-hoc correction. P values less than
0.05 were considered statistically significant. Data are presented as
mean ± standard error of mean (SEM). Statistical analyses were
performed with Prism 5.0 software (GraphPad Software Inc., La
Jolla, CA, USA).
Study approval
FA MSPC were generated from BM cells of five FA patients from
the Institute of Hematology and Blood Diseases Hospital, Chinese
Academy of Medical Sciences & Peking Union Medical College
and Indiana University School of Medicine. Written informed con-
sent was obtained from all patients. The study was approved by
the Ethics Committee of the Institute of Hematology and Blood
Diseases Hospital, Chinese Academy of Medical Sciences, and
Indiana University School of Medicine according to guidelines of
the 1975 Helsinki Declaration.
Results 
Hematopoietic defects in double knockout mice are
associated with a dysfunctional bone marrow 
microenvironment
We have previously reported that Fancc/g DKO mice
develop progressive hematologic abnormalities, including
BMF, acute myeloid leukemia, and myelodysplastic syn-
drome, which closely mimic hematopoietic disorders
observed in FA patients.27 To assess the contribution of the
microenvironment to the hematopoietic phenotype of
DKO mice, we performed reciprocal transplantation
experiments whereby hematopoietic cells from WT and
DKO mice were transplanted into lethally irradiated WT
or DKO recipients. The survival rate was lowest in the
cohort of DKO mice reconstituted with DKO BM cells
among the four groups (Figure 1A). DKO BM transplanted
into WT recipients also caused reduced survival as com-
pared to WT BM transplanted into WT recipients, due to
the occurrence of BM dysplasia and BMF. Intriguingly,
DKO recipient mice transplanted with WT BM cells also
exhibited impaired survival and BM dysplastic pheno-
types indicated by hematologic analysis, suggesting a
putative role for an impaired marrow niche in DKO mice.
In addition, an expanded granulocyte-macrophage pro-
genitor compartment was observed in DKO recipient
mice transplanted with WT BM cells compared to WT
recipients (Online Supplementary Figure S1A). Furthermore,
we observed a 25% or 60% reduction in the total number
of colony-forming unit-cells (CFU-C) in DKO as compared
to WT recipient mice transplanted with WT or DKO BM
cells, respectively (Figure 1B). Consistently, a significantly
hypoplastic BM was observed in WT or DKO recipients
transplanted with either DKO or WT BM cells, respective-
ly, with the most severe BM hypoplasia occurring in DKO
recipients reconstituted with DKO BM cells (Figure 1C).
The histology of the spleens of DKO recipients with either
WT or DKO BM cells revealed disrupted architecture.
Lymphoid aggregates in the white pulp (disrupted archi-
tecture) of DKO recipient spleens were also smaller than
those of WT recipients (Figure 1D). May-Grünwald-
Giemsa stained peripheral blood smears prepared from
DKO recipients showed dysplastic features, including
hyposegmented (bilobed) neutrophils with fine nuclear
bridging consistent with pseudo-Pelger-Huët cells (Figure
1E, b-d, red arrows, Online Supplementary Figure S1B) and
monocytes (Figure 1E, f-h, green arrows), whereas blasts
were rare. In addition, dysplastic megakaryocytes (multin-
uclear megakaryocytes and hyposegmented megakaryo -
cytes) were observed in the BM of DKO recipients trans-
planted with WT BM cells, but not in WT recipient mice
(Online Supplementary Figure S1C). These data suggest that
DKO recipient mice transplanted with WT or DKO BM
cells develop a myelodysplastic syndrome-like disease33
and provide strong in vivo evidence that the niche plays a
cooperative role in the pathogenesis of impaired marrow
engraftment in the DKO FA mouse model. 
Impaired skeletal development and bone mass deficits
in double knockout mice
Skeletal anomalies including short stature and osteope-
nia/osteoporosis are widespread among the FA popula-
tion.34 We, therefore, sought to ascertain the impact of
Fancc/g genetic inactivation on skeletal development. The
body length and body weight (Online Supplementary Figure
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Figure 3. In vitro analysis of mesenchymal stem pro-
genitor cell frequency and osteoblast differentiation.
(A) The frequency of CFU-F per 4×106 BMMNC from WT
and DKO mice is shown (n=9 mice per genotype). Data
are presented as mean ± SEM, ***P<0.001, two-tailed
Student t-test. (B) Significant reduction of CFU-F in DKO
mice at different cell passages (n=9 mice per geno-
type). Data are presented as mean ± SEM,
***P<0.001, two-tailed Student t-test. (C) The frequen-
cy of CFU-osteoblasts in WT and DKO mice is shown
(n=5 mice per genotype). Alkaline phosphatase staining
of WT and DKO BMMNC cultured in osteogenic medi-
um. Data are presented as mean ± SEM, ***P<0.001,
two-tailed Student t-test. (D) The ratio of Oil Red O-pos-
itive adipocytes to total colonies demonstrated
enhanced adipocyte differentiation in DKO mice com-
pared to WT ones (n=5 mice per genotype). Data are
presented as mean ± SEM, **P<0.01, two-tailed
Student t-test. Scale bar: 100 μm (E) Significantly
reduced Runx2, Cdh2 and increased Ppar-γ gene
expression in DKO MSPC as compared to WT controls
(n=5 mice per genotype). Data are presented as mean
± SEM, *P<0.05, two-tailed Student t-test.
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S2A,B) of DKO mice were significantly reduced as com-
pared to those of age- and sex-matched WT littermates.
Whole body bone mineral density, determined by
pDEXA, was also reduced in DKO mice as compared to
WT controls (Figure 2A), with an even more substantial
reduction in femoral bone mineral density of the DKO
mice versus WT controls (Figure 2B). Consistent with the
decreased bone mass in DKO mice determined by bone
mineral density analysis, micro-computed tomography
analysis of the animals at 6 months of age revealed
decreased bone volume in the mid-shaft of DKO femora
compared to WT controls (Figure 2C,D). Quantitative his-
tomorphometric analysis also revealed significantly
reduced bone volume in DKO femora versus WT ones
(Online Supplementary Figure S2C).
Alterations in skeletal homeostasis can occur secondary
to imbalances between bone-forming osteoblast activity
and osteoclast-mediated bone resorption. To further
assess osteoblast and osteoclast development in vivo, quan-
titative histomorphometry was performed on histological
sections from the distal femoral metaphysis stained with
hematoxylin and eosin (H&E), McNeal, and the osteoclast
enzyme TRAP (Figure 2E,F, Online Supplementary Figure
S2D,E). Sections stained with H&E revealed a marked
reduction in trabecular and cortical bone in DKO femora
as compared to WT control femora (Figure 2E, a-d).
Manually counting osteoblasts in the femoral trabecular
bone on McNeal-stained sections revealed that the num-
ber of osteoblasts was singnificantly lower in DKO mice
than in WT controls (Figure 2E, e-h, Figure 2F). In addition,
a significantly increased osteoclast surface to bone surface
ratio was observed in DKO mice than in WT controls, as
assessed by scoring the TRAP-positive staining osteoclast
surface in the femoral trabeculae normalized to the trabec-
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Figure 4. Co-culture of double knockout
mesenchymal stem/progenitor cells with
hematopoietic stem/progenitor cells
showed the decreased hematopoietic
supportive activity.  (A, B) DKO MSPC had
reduced hematopoietic supportive activi-
ty as compared with WT MSPC (n=3 mice
per genotype). Data are presented as
mean ± SEM, *P<0.05, **P<0.01,
***P<0.001, two-way ANOVA followed by
the Bonferroni test. (C, D) DKO MSPC sup-
ported HSC cultures contained higher
percentages of the Gr1+/Mac1+ popula-
tion and apoptotic CD45+ cells (n=3 mice
per genotype). Data are presented as
mean ± SEM, *P<0.05, **P<0.01,
***P<0.001, two-way ANOVA followed by
the Bonferroni test. (E) MSPC-conditioned
medium, adipocyte-conditioned medium,
and the serum of DKO mice contained
significantly increased concentrations of
tumor necrosis-α (TNF-α) as compared
with WT mice (n=3 mice per genotype).
Data are presented as mean ± SEM,
*P<0.05, **P<0.01, two-tailed Student t-
test. (F) A marked reduction of the inter-
leukin-6 (IL6) level was observed in DKO
MSPC conditioned medium (n=3 mice per
genotype). Data are presented as mean ±
SEM, ***P<0.001, two-tailed Student t-
test.
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ular bone surface (Figure 2G, Online Supplementary Figure
S2D). To study dynamic changes in bone remodeling, WT
and DKO mice were injected with fluorochrome markers
to label the bone surface (Online Supplementary Figure
S2E).35 A 23% reduction in the mineralizing surface
(MS/BS, Figure 2H, Online Supplementary Table S1), a 17%
reduction in mineral apposition rate (MAR, Figure 2I,
Online Supplementary Table S1), and a 36% reduction in
bone formation rate (BFR)/BS were observed in DKO mice
as compared to age- and sex-matched WT controls (Online
Supplementary Figure S2F, Online Supplementary Table S1).
Collectively, these data suggest that abnormal osteoblast-
and osteoclast-mediated bone turnover in DKO mice leads
to pathological bone remodeling.
Fancc/g genetic ablation alters mesenchymal
stem/progenitor cell fates, favoring adipogenic 
versus osteoblastic differentiation
As osteoblasts, the principal cells mediating bone forma-
tion were deficient in DKO mice (Figure 2F), we hypothe-
sized that Fancc/g deficiency alters the proliferative and/or
differentiative capacity of MSPC, which give rise to
mature osteoblasts and their precursors. We, therefore,
performed colony-forming unit-fibroblast (CFU-F) assays
on BM cells of the mice to determine the frequency of
MSPC in WT versus DKO mice in vivo. DKO BM exhibited
a significant reduction in the number of CFU-F compared
to the marrow of WT littermates (Figure 3A,B).
Consistently, flow cytometric analysis showed that the
frequency of CD45-CD146+Nestin+CD105+ MSPC was sig-
nificantly decreased in the BM of DKO mice compared to
WT controls (Online Supplementary Figure S3A).
Phenotypically defined MSPC from BM of DKO and WT
mice were used to conduct the following experiments
(Online Supplementary Figure S3B), and a significant reduc-
tion of CD146 expression was observed in DKO MSPC
compared to WT MSPC. A thymidine incorporation assay
demonstrated that DKO MSPC had significantly less pro-
liferative potential compared to WT MSPC (Online
Supplementary Figure S3C).
As one of the fundamental properties of MSPC is their
capacity to differentiate into multiple lineages under spe-
cific culture conditions,36 we next determined whether
Fancc/g deletion altered MSPC lineage commitment by
performing osteoblast and adipogenic differentiation
assays. Alkaline phosphatase activity is an indicator of
successful differentiation of MSPC into osteoblasts.37
Compared to WT MSPC, DKO MSPC exhibited markedly
reduced alkaline phosphatase staining following incuba-
tion in osteogenic differentiation medium, indicating
impaired osteoblast differentiation (Figure 3C). In con-
trast, when MSPC were cultured in adipogenic medium
for 14 days, a significantly increased Oil Red O-positive
area was observed in DKO cultures compared to WT con-
trols (Figure 3D), suggesting that DKO MSPC had an
increased capacity of adipocyte differentiation. These
results indicate that Fancc/g deficiency leads to impaired
MSPC proliferation (as determined by CFU-F) and lineage
skewing, favoring adipocyte commitment over osteoblast
differentiation. 
To delineate the molecular basis of impaired cell fate
determination in DKO MSPC, we used quantitative poly-
merase chain reaction analysis to examine the expression
of critical genes governing lineage commitment of MSPC,
including osteoblasts, and adipocytes in WT versus DKO
cells. Our results indicated that the expression of genes
controlling osteoblast differentiation, such as Runx2 and
N-cadherin (Cdh2), were significantly reduced in DKO
MSPC compared to WT controls (Figure 3E). In contrast, a
marked increase in the expression of the adipogenic tran-
scription factor, Ppar-γ, was observed in DKO MSPC com-
pared to WT MSPC (Figure 3E). These data indicate that
Fancc/g deletion alters gene expression programs govern-
ing lineage commitment of MSPC, leading to deregulated
adipocyte and osteoblast lineage commitment.
Osteoclasts are specialized cells derived from the mono-
cyte/macrophage hematopoietic lineage which adhere to
the bone surface, secreting acid and lytic enzymes that
degrade the bone matrix. To determine whether genetic
ablation of Fancc/g alters osteoclast development, we
established osteoclast cultures from BMMNC in the pres-
ence of the osteoclast differentiating cytokines M-CSF and
RANK-L. DKO BMMNC exhibited a significantly
increased propensity to osteoclast differentiation com-
pared to WT BMMNC, as quantified by TRAP staining
(Online Supplementary Figure S3D). Collectively, these data
indicate that functional imbalances between osteoblast
and osteoclast differentiation in the context of Fancc/g
deficiency might cooperate to alter bone remodeling in
vivo, contributing to short stature and osteoporosis in
DKO mice as shown in Figure 2.
Double knockout mesenchymal stem/progenitor cells
exhibit defective hematopoietic supportive activity 
in vitro
MSPC and their progeny, such as osteoblasts and
adipocytes, are widely recognized to play a critical role in
supporting hematopoietic cells within the BM niche.38,39
Given that DKO MSPC exhibit impaired expansion and
differentiation, we sought to explore further the role of
Fancc/g in maintaining MSPC hematopoietic supportive
activity. We began by performing cobblestone area-form-
ing cell (CAFC) assays to evaluate the hematopoietic sup-
portive activity of DKO MSPC. When hematopoietic pro-
genitors (LK cells) were co-cultured for 4 weeks on MSPC
feeder layers, significantly reduced CAFC numbers were
observed when using DKO MSPC compared to WT
MSPC, suggesting impaired hematopoietic supportive
activity by DKO MSPC (Figure 4A,B). To further assess
whether Fancc/g deficiency alters the capacity of MSPC to
maintain hematopoietic cell differentiation, the percent-
age of Gr1+/Mac1+ cells following 4 weeks of co-culture
was determined by flow cytometry. As shown in Figure
4C, significantly increased percentages of Gr1+/Mac1+ cells
were observed in DKO MSPC-supported WT and DKO
LK hematopoietic cell cultures compared to WT MSPC,
indicating an enhancement of myeloid differentiation.
Consistently, a significantly increased percentage of
Gr1+/Mac1+ cells was observed in the peripheral blood of
DKO recipients transplanted with either WT or DKO BM
cells, compared with the WT recipients (Online
Supplementary Figure S4A). In addition, DKO MSPC-sup-
ported cultures contained increased percentages of apop-
totic CD45+ cells (Figure 4D). Collectively, these findings
indicate that Fancc/g-deleted MSPC increase myeloid cell
differentiation in vitro compared to WT MSPC.
Secretion of trophic and paracrine factors within the BM
niche is regarded to be a central mechanism by which
MSPC function to maintain hematopoiesis. We, therefore,
hypothesized that deregulated secretion of paracrine fac-
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tors might account for the impaired hematopoietic sup-
portive activity of DKO MSPC. Tumor necrosis factor-
alpha (TNF-α) is an inflammatory cytokine, which has
been shown to preferentially induce apoptosis in FA
hematopoietic cells.40,41 An enzyme-linked immunosor-
bent assay showed a significantly increased level of TNF-
α in DKO MSPC supernatants (Figure 4E). In addition to
MSPC, adipocytes are known to be another major source
of TNF-α production.42,43 Consistent with these data, we
observed a 4.5-fold increase in the concentration of TNF-
α in conditioned media collected from DKO adipocyte
cultures compared to WT controls (Figure 4E). As further
validation, significantly increased concentrations of TNF-
α were also observed in the serum of DKO mice as com-
pared to that of WT mice (Figure 4E). By contrast, levels of
the hematopoietic supportive cytokine interleukin-6 were
found to be markedly reduced in DKO MSPC conditioned
medium (Figure 4F). HSC can lose stem cell capacity and
die after exposure to ROS; DKO MSPC exposed to H2O2
produced increased ROS compared to their WT counter-
part (Online Supplementary Figure S4B). This enhanced ROS
production has also been identified along with the senes-
cence and adipocyte differentiation of MSPC,44,45 which is
consistent with the characteristics of the DKO MSPC.
Taken together, these data suggest that loss of Fancc/g in
MSPC alters the production of multiple cytokines and
ROS, which may serve to perpetuate dysfunctional
hematopoiesis in DKO mice.
Human Fanconi anemia patient-derived and double
knockout mesenchymal stem/progenitor cells exhibit
similar cellular phenotypes
To examine whether MSPC derived from FA patients
exhibit similar phenotypes to those observed in DKO
mice, MSPC were isolated from four patients with a clini-
cal diagnosis of FA (Online Supplementary Table S2) and
healthy volunteers by culturing BM cells in human
MesenCult medium and phenotypically validating the
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Figure 5. Impaired cellular functions of Fanconi anemia patient-derived mesenchymal stem/progenitor cells. (A)
FA MSPC were more sensitive to mitomycin C (MMC). Data are presented as mean ± SEM and represent one of four
independent experiments. (B) FA MSPC had an increased rate of senescence as compared to control MSPC. Data
are shown as mean ± SEM from triplicate wells (5 fields/well) and represent one of four independent experiments.
***P<0.001, two-tailed Student t-test. (C) Representative images demonstrating alkaline phosphatase (ALP) stain-
ing of a healthy donor and FA MSPC cultured in the osteogenic medium surface. (D) FA MSPC had impaired
osteoblast differentiation. Data are presented as mean ± SEM from triplicate wells (6 fields/well) and represent
one of four independent experiments. ***P<0.001, two-tailed Student t-test. (E, F) FA MSPC had impaired
hematopoietic supportive activity. Data are presented as mean ± SEM from triplicate wells and represent one of
four independent experiments. *** P<0.001, two-tailed Student t-test. Each experiment was performed with a dif-
ferent MSPC culture isolated from the individual patient.
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cells by flow cytometry (Online Supplementary Figure S5A).
Sensitivity to mitomycin C was determined as previously
described30 and was greater in FA MSPC than in healthy
control MSPC (Figure 5A). Cellular senescence is a key
pathophysiological phenomenon characterized by cell
cycle arrest and upregulation of senescence-associated β-
galactosidase activity. A 3-fold increase in the percentage
of senescent cells was observed in FA MSPC compared to
control MSPC (Figure 5B, Online Supplementary Figure S5B).
Like DKO MSPC, human FA MSPC exhibited markedly
defective osteoblast differentiation (Figure 5C,D) and
increased adipocyte differentiation (Online Supplementary
Figure S5C). Furthermore, osteoblast numbers were signif-
icantly reduced in BM biopsy sections from FA patients
compared to those from healthy controls (Online
Supplementary Figure S5D,E).
To evaluate the hematopoietic supportive activity of
these MSPC, MSPC from FA patients were co-cultured
with cord blood CD34+ cells. After 5 weeks of co-culture,
CAFC were counted, and CFU-C assays were performed.
Significantly lower numbers of CAFC (Figure 5E) and
CFU-C (Figure 5F) were observed in the co-cultures of FA
MSPC with CD34+ cells than in those of healthy control
MSPC with CD34+ cells. These data suggest that MSPC
derived from FA patients exhibit impaired HSPC support-
ive activity, which is consistent with the findings in MSPC
from DKO mice. 
To test whether MSPC derived from healthy donor BM,
compared to FANCG-deficient MSPC, would enhance the
engraftment of human FANCG-deficient BM cells in vivo,
MSPC were injected intra-tibially into sub-lethally irradi-
ated NOD.Cg-Prkdcscid IL2rgtm1Wjl/Sz (NS2) recipient mice.
Twenty-four hours later, BMMNC from a human FANCG-
deficient patient were delivered via tail vein injection. Four
months following co-transplantation, human (h) CD45+
cell engraftment in the BM of recipient mice was analyzed
by flow cytometry. Injection of healthy MSPC dramatical-
ly enhanced FANCG BMMNC engraftment (19% of
hCD45+ cells, Online Supplementary Figure S5F, right panel),
while the percentage of hCD45+ cells in the mice that
received FANCG MSPC and FANCG BMMNC was only
0.9% (Online Supplementary Figure S5F, left panel).
Discussion 
MSPC act as an essential component of the BM
hematopoietic microenvironment and have been proven
to be involved in the pathogenesis of several hematologic
malignancies.46,47 A recent translational study by Dong et
al. found that Ptpn11-activating mutations in the BM
MSPC and osteoprogenitors cause a juvenile myelomono-
cytic leukemia-like cancer in mice through profound,
detrimental effects on HSC.48 Several previous studies
indicated that MSPC from FA patients display reduced
long-term proliferation ability and spontaneous chromo-
some breakages.49-51 In addition, we have previously
reported that MSPC from the murine Fancg-/- model exhib-
it impaired proliferative capacity.30 Amarachintha et al. also
reported that MSC from Fanca-/- or Fancd2-/- mice impaired
WT HSPC self-renewal and induced myeloid expansion.52
Although another study showed that BM MSPC did not
have impaired function and contribute to the pathogenesis
of the disease in acquired BMF such as aplastic anemia,53
recent studies by Zambetti et al. demonstrated that mes-
enchymal niche-derived inflammatory signaling induces
oxidative and genotoxic stress in HSPC in Shwachman-
Diamond syndrome, a rare inherited BMF syndrome.54
Whether defects of BM MSPC are involved in the patho-
physiology of FA deserves further in vivo investigation.
FA is caused by a mutation in genes encoding proteins
required for the FA pathway. Although FA patients are
clinically characterized by congenital mesenchymal anom-
alies, and a uniformly progressive and fatal BMF which
begins in infancy or childhood,20,55-58 the impact of the loss
of FA genes on other stem cell compartments and the role
of the BM niche in the pathogenesis of FA-dependent BMF
have received limited attention. To date, more than ten FA
genes have been deleted or mutated in the mouse, but
none of these mouse models with single FA gene deficien-
cy spontaneously develops severe hematologic abnormal-
ities like FA patients.59,60 We have previously reported that
Fancc/g DKO mice spontaneously develop more aggres-
sive hematopoietic deficits including BMF, acute myeloid
leukemia, and myelodysplastic syndrome.27 Here, using
the DKO murine model, we provided evidence that
Fanc/g-deficient MSPC within the hematopoietic microen-
vironment cooperate to engender dysfunctional
hematopoiesis. These results provide new insights regard-
ing the fundamental mechanisms by which the BM
“niche” contributes to the pathogenesis of FA-dependent
BMF. Furthermore, we demonstrated that Fancc/g-defi-
cient MSPC lead to impaired osteoblast differentiation
with concomitant lineage skewing toward adipocyte com-
mitment. Genetic ablation of Fancc/g also altered the pro-
duction of critical inflammatory cytokines including inter-
leukin-6 and TNF-α, the latter of which is known to
induce HSPC apoptosis and contribute to BMF.
Collectively, this study reveals an intimate relationship
between FA HSPC and the BM niche in the pathogenesis
of hematopoietic deficits. 
Our study provides strong evidence that Fancc/g defi-
ciency results in multiple skeletal pathologies, including
reduced body size and low bone mass phenotypes. These
phenotypes in mice recapitulate the clinical features of
short stature and osteoporosis common in FA patients.61
Bone remodeling is a dynamic process controlled by the
coordinated activity of osteoblast-mediated bone forma-
tion and osteoclast-mediated bone resorption. We attrib-
ute the bone mass deficits in DKO mice in part to reduced
osteoblast activity, as evidenced by the reduced osteoblast
numbers and impaired bone remodeling in vivo. 
Like HSC, MSPC have the potential to differentiate into
multiple lineages, including osteoblasts, adipocytes, and
chondrocytes. The balance between osteogenesis and
adipocyte formation is required for normal niche activity
to maintain hematopoiesis.62-65 Our in vitro and in vivo stud-
ies indicate that Fancc/g deficiency impairs the differenti-
ation of MSPC into osteoblasts while favoring adipocyte
differentiation. Meanwhile, DKO mice exhibit reduced
MSPC numbers and impaired self-renewal, suggesting an
association between dysfunctional DKO MSPC and
abnormal skeletal development/homeostasis in the DKO
mouse model. DKO MSPC displayed dysregulated expres-
sion of multiple key genes controlling osteoblast versus
adipocyte lineage commitment including Runx2, Cdh2,
and Ppar-γ. Cdh2 has been identified as a negative regula-
tor of adipogenesis.66 Therefore, skewed lineage commit-
ment of DKO MSPC away from osteoblast differentiation
and toward adipocyte commitment may be associated
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with reduced Cdh2 expression. In addition, we observed a
significant reduction of CD146 expression in DKO MSPC
compared to WT MSPC. Since CD146 has been reported
to be a marker for multilineage differentiation capacity,67
the fewer CD146+ cells in DKO MSPC might be associated
with the defective MSPC functions. Consistent with
murine data, MSPC obtained from BM biopsies of FA
patients also revealed impaired proliferation and
osteoblast differentiation capacity. 
MSPC-HSPC co-culture assays further revealed that
MSPC from DKO mice and FA patients have defective
hematopoietic supportive activity, as evidenced by
reduced CAFC and CFU-C formation. Dysregulated skele-
tal remodeling and impaired osteoblast differentiation in
DKO mice may thus contribute to the defective BM
microenvironment, which is unable to sustain adequate
HSPC numbers. These results are consistent with findings
by Morad et al. who showed that the hematopoietic sup-
portive activity of MSPC is influenced by lineage determi-
nation.68
It has been previously demonstrated that FA HSPC are
hypersensitive to TNF-α induced apoptosis and increased
levels of TNF-α and other inflammatory cytokines have
been observed in FA patients.26,69,70 Here we observed
reduced levels of interleukin-6 and significantly higher lev-
els of inflammatory cytokines, including TNF-α, in the
DKO model. Nagajyothi et al. previously reported that
adipocytes are the major source of circulating inflammato-
ry cytokines.71,72 It is also known that adipocytes negative-
ly regulate hematopoietic activity and that TNF-α plays an
important role in the pathogenesis of BMF.38,73,74
In addition, we observed that co-transplantation of
healthy donor MSPC enhanced the engraftment and
expansion of human BMMNC from an FANCG patient in
vivo in NS2 mice while FA MSPC failed to support FA BM
cell reconstitution. Nevertheless, studies in a larger cohort
of NSG mice with the co-transplantation of MSPC and FA
BM cells are warranted in the future.
Collectively, these data suggest that the pathogenesis of
hematopoietic deficits in FA is complex and likely depends
on the interplay between abnormal hematopoietic cells
and a dysfunctional BM niche. Our study indicates that FA
MSPC have skewed differentiation capacity, altered
cytokine secretion and defective hematopoietic supportive
activity, providing scientific insight into the role of FA
mutations in impairing the hematopoietic niche and their
involvement in the pathogenesis of BMF. Clinically, a
more detailed understanding of the disease might lead to
rethink about the niche for the development of new ther-
apies for FA. While MSPC are increasingly appreciated to
be a critical part of the niche, due to the anatomical struc-
ture of the niche, future studies to dissect the role of other
niche components, e.g., the endothelial niche or MSPC
progenies, with specific deletion of FA genes using
Cre/loxP technology are warranted.
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